This is a preview of subscription content, log in via an institution to check access.
Notes
PMDA = Pharmaceuticals and Medical Devices Agency
References
Pharmaceuticals and Medical Devices Agency of Japan. Revision of Precautions - Amantadine hydrochloride. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225502.pdf.
Pharmaceuticals and Medical Devices Agency of Japan. Revision of Precautions - Oseltamivir phosphate. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225504.pdf.
Pharmaceuticals and Medical Devices Agency of Japan. Revision of Precautions - Zanamivir hydrate, Laninamivir octanoate hydrate. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225506.pdf.
Pharmaceuticals and Medical Devices Agency of Japan. Revision of Precautions - Baloxavir marboxil. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225508.pdf.
Pharmaceuticals and Medical Devices Agency of Japan. Revision of Precautions - Favipiravir. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225509.pdf.
Pharmaceuticals and Medical Devices Agency of Japan. Revisions of Precautions - Peramivir hydrate. Internet Document : [2 pages], 21 Aug 2018. Available from: URL: http://www.pmda.go.jp/files/000225511.pdf.
Rights and permissions
About this article
Cite this article
PMDA labelling changes regarding neuropsychiatric symptoms. Reactions Weekly 1718, 3 (2018). https://doi.org/10.1007/s40278-018-51347-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-51347-z